Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of low-dose atropine eye drops for pediatric myopia progression
ChiCTR2500097540Phase 3Completed
- Sponsor
- Beijing Tongren Hospital
- Start
- Apr 2024
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atropine in myopia (3 arms), sponsored by Beijing Tongren Hospital. Primary endpoints: Change from baseline in cycloplegic spherical equivalent at week 96: 0.02% atropine versus placebo and Change from baseline in cycloplegic spherical equivalent at week 96: 0.01% atropine versus placebo. Started Apr 2024; status: completed.
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on ChiCTR2500097540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097540.